Evidence map›Paper›PMID 38717935›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Blood biomarkers of Alzheimer's disease in the community: Variation by chronic diseases and inflammatory status.

Martina Valletta, Davide Liborio Vetrano, Debora Rizzuto, Bengt Winblad, Marco Canevelli, Sarah Andersson, Matilda Dale, Claudia Fredolini, Laura Fratiglioni, Giulia Grande

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Physical activity, aerobic fitness, and AD blood biomarkers: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Multimorbidity in dementia: Current perspectives and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martina VallettaAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.ORCID 0000-0003-0139-8287
Davide Liborio VetranoAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Debora RizzutoAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Bengt WinbladDivision of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Marco CanevelliAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Sarah AnderssonAffinity Proteomics Stockholm, Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Royal Institute of Technology (KTH), Solna, Sweden.
Matilda DaleAffinity Proteomics Stockholm, Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Royal Institute of Technology (KTH), Solna, Sweden.
Claudia FredoliniAffinity Proteomics Stockholm, Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Royal Institute of Technology (KTH), Solna, Sweden.
Laura FratiglioniAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Giulia GrandeAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.

Funding

Gamla Tjänarinnor foundation 2021-01235Hjärnfonden 2021-0025Karolinska Institutet Strategic Research Area in Epidemiology and Biostatistics (SFOEpi)Stiftelsen Sigurd och Elsa Goljes minne LA2023-0113Swedish Ministry of Health and Social AffairsSwedish Research Council 2021-00178Swedish Research Council 2021-03324
6 · The paper itself

Abstract

introductionWe explored the variations of blood biomarkers of Alzheimer's disease (AD) by chronic diseases and systemic inflammation.

methodsWe explored the association of AD blood biomarkers with chronic diseases and systemic inflammation (interleukin-6 [IL-6]), in 2366 dementia-free participants of the Swedish National Study on Aging and Care-in Kungsholmen, using quantile regression models.

resultsA greater number of co-occurring chronic diseases was associated with higher concentrations of phosphorylated-tau 181 (p-tau181), total-tau (t-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) (p < 0.01). Anemia, kidney, cerebrovascular, and heart diseases were associated with variations in the levels of AD blood biomarkers. Participants in the highest (vs. lowest) interleukin-6 (IL-6) tertile had higher NfL concentration. Systemic inflammation amplified the associations between several chronic diseases and p-tau181, t-tau, NfL, and GFAP. DISCUSSION: In the community, the concentration of AD blood biomarkers varies in relation to medical conditions and systemic inflammation. Recognizing these influences is crucial for the accurate interpretation and clinical implementation of blood biomarkers. HIGHLIGHTS: Participants with a complex clinical profile (i.e., multiple co-occurring diseases or specific disease combinations) display elevated levels of AD blood-biomarkers. Anemia, heart, cerebrovascular, and kidney diseases are associated with variations is the levels of AD blood biomarkers in cognitively intact older adults. Systemic inflammation amplifies the association between several chronic diseases and AD blood biomarkers.

Indexed as

Alzheimer DiseaseBiomarkersInflammationInterleukin-6tau ProteinsAgedAged, 80 and overChronic DiseaseFemaleGlial Fibrillary Acidic ProteinHumansMaleNeurofilament ProteinsSwedenBiomarkersGlial Fibrillary Acidic ProteinInterleukin-6neurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer's diseaseblood biomarkerschronic diseasesdementiainflammationpopulation‐based study

Identifiers

PMID38717935
PMCPMC11180869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.